Back to top
more

Ecolab (ECL)

(Delayed Data from NYSE)

$272.87 USD

272.87
833,178

+3.10 (1.15%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $272.78 -0.09 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 33% (163 out of 244)

Industry: Chemical - Specialty

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Indrajit Bandyopadhyay headshot

Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now

by Indrajit Bandyopadhyay

Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.

Zacks Equity Research

Reasons to Add Masimo (MASI) Stock to Your Portfolio Now

by Zacks Equity Research

Masimo's (MASI) R&D activities raise optimism about the stock.

Zacks Equity Research

Innospec (IOSP) & IJM Collaborate to Protect Palm Oil Workers

by Zacks Equity Research

Innospec (IOSP) partners with IJM to combat forced labor in the Southeast Asia palm oil sector.

Zacks Equity Research

Tronox (TROX) Inks Long-Term Power Purchase Deal With NOA

by Zacks Equity Research

The agreement is another example of Tronox's (TROX) ongoing projects and investments aimed at achieving its publicly stated objective of net zero greenhouse gas emissions by 2050.

Zacks Equity Research

What Makes L.B. Foster (FSTR) Stock a Solid Choice Right Now

by Zacks Equity Research

L.B. Foster (FSTR) offers a strong investment opportunity with stellar first-quarter earnings, promising growth prospects and solid operational performance set to continue through 2024.

Zacks Equity Research

Air Liquide (AIQUY) to Build Gas Facility for Chip Production

by Zacks Equity Research

Air Liquide (AIQUY) is investing $250 million in an Idaho gas facility to support Micron Technology's new semiconductor fab, enhancing U.S. supply chain resilience.

Zacks Equity Research

DexCom's (DXCM) G7 CGM System Now Connects to Apple Watch

by Zacks Equity Research

DexCom (DXCM) announces the direct connectivity of its G7 CGM system to Apple Watch for users in the United States, the UK, and Ireland.

Zacks Equity Research

Cabot (CBT) Gets Operation Clean Sweep Europe Certification

by Zacks Equity Research

Cabot (CBT) is one of Europe's first black masterbatch manufacturers to receive this third-party certification.

Zacks Equity Research

Chemours (CC) Announces Enhancement of EVOLVE 2030 Methodology

by Zacks Equity Research

The revised EVOLVE 2030 approach improves Chemours' (CC) ability to integrate its business processes with this goal.

Zacks Equity Research

Glaukos (GKOS) Gains 40.4% YTD: What's Driving the Rally?

by Zacks Equity Research

Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.

Zacks Equity Research

Stryker's (SYK) LIFEPAK 35 to Offer Advanced Monitoring System

by Zacks Equity Research

Stryker (SYK) announces the launch of LIFEPAK 35 monitor/defibrillator, which is likely to aid emergency responders to reduce cognitive load during demanding situations by improving workflow.

Zacks Equity Research

WestRock's (WRK) VPPA Project With ENGIE Becomes Operational

by Zacks Equity Research

WestRock's (WRK) first VPPA Project with ENGIE is now operational, marking a step forward to achieving 2030 science-based greenhouse gas targets.

Zacks Equity Research

Universal Stainless (USAP) Surges 48% in 3 Months: Here's Why

by Zacks Equity Research

Universal Stainless' (USAP) rally reflects a robust first-quarter performance on the back of record aerospace sales.

Zacks Equity Research

ArcelorMittal (MT) & Materialise Partner for Metal 3D Printing

by Zacks Equity Research

ArcelorMittal (MT) and Materialise join forces to enhance LPBF and metal 3D printing using advanced build processors and specialized steel powders.

Zacks Equity Research

PPG Achieves 40% Reduction in Overspray Using SIGMAGLIDE 2390

by Zacks Equity Research

PPG strongly believes in the long-term viability of electrostatic application and is promoting it in shipyards around Europe, Singapore and China.

Zacks Equity Research

DexCom (DXCM) Declines on Potential Competition for Stelo (revised)

by Zacks Equity Research

DexCom (DXCM) stock declined on Monday following the FDA approval of another over-the-counter glucose monitor, potentially fueling competition for Stelo.

Zacks Equity Research

Stryker's (SYK) Acquisition of Artelon Set to Expand Its Market

by Zacks Equity Research

Stryker (SYK) announces the signing of the definitive agreement to acquire a privately held company, Artelon, to strengthen its foothold in the soft tissue fixation market.

Zacks Equity Research

Here's Why You Should Retain Nevro (NVRO) Stock for Now

by Zacks Equity Research

Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.

Zacks Equity Research

Nucor (NUE) Expands Portfolio With $565M Acquisition of Rytec

by Zacks Equity Research

Nucor (NUE) is acquiring Rytec Corporation for $565 million to expand its product portfolio and leverage cross-selling opportunities in the commercial doors market.

Zacks Equity Research

BASF (BASFY) Divests Bioenergy Enzymes Business to Lallemand

by Zacks Equity Research

BASF (BASFY) continues to concentrate on its enzyme activities in the animal feed and detergent sectors.

Zacks Equity Research

Hawkins (HWKN) Acquires Intercoastal Trading in Maryland

by Zacks Equity Research

Hawkins (HWKN) anticipates that the purchase of Intercostal Trading will be accretive to earnings per share this fiscal year.

Zacks Equity Research

Inari's (NARI) Expanding Product Portfolio Offsets Competition

by Zacks Equity Research

Inari's (NARI) VTE products are driving its top line on the back of robust adoption. The company is expanding in additional indications to fuel growth and fight competition.

Zacks Equity Research

DexCom (DXCM) Declines on Potential Competition for Stelo

by Zacks Equity Research

DexCom (DXCM) stock declined on Monday following the FDA approval of another over-the-counter glucose monitor, potentially fueling competition for Stelo.

Zacks Equity Research

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

by Zacks Equity Research

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Zacks Equity Research

Three Reasons to Retain BD (BDX) Stock in Your Portfolio Now

by Zacks Equity Research

BD's (BDX) robust product portfolio raises optimism about the stock.